Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: macrogol 8000; ethylcellulose; titanium dioxide; hyprolose; hypromellose; colloidal anhydrous silica; lactose; magnesium stearate - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: iron oxide red; hyprolose; macrogol 8000; titanium dioxide; colloidal anhydrous silica; lactose; ethylcellulose; hypromellose; magnesium stearate - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 15 mg - tablet, modified release - excipient ingredients: hypromellose; hyprolose; macrogol 8000; colloidal anhydrous silica; titanium dioxide; ferrosoferric oxide; lactose; iron oxide red; magnesium stearate; ethylcellulose - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; iron oxide yellow; hyprolose; hypromellose; iron oxide black; colloidal anhydrous silica; lactose; titanium dioxide; macrogol 8000; iron oxide red; ethylcellulose - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: titanium dioxide; hypromellose; ethylcellulose; iron oxide yellow; magnesium stearate; macrogol 8000; colloidal anhydrous silica; lactose; hyprolose - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: magnesium stearate; iron oxide yellow; macrogol 8000; lactose; hyprolose; colloidal anhydrous silica; titanium dioxide; hypromellose; ethylcellulose - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Canada - English - Health Canada

pharmascience inc - oxycodone hydrochloride - tablet - 5mg - oxycodone hydrochloride 5mg - opiate agonists

Canada - English - Health Canada

pharmascience inc - oxycodone hydrochloride - tablet - 10mg - oxycodone hydrochloride 10mg - opiate agonists

Canada - English - Health Canada

pharmascience inc - oxycodone hydrochloride - tablet - 20mg - oxycodone hydrochloride 20mg - opiate agonists

Canada - English - Health Canada

laboratoire riva inc. - oxycodone hydrochloride - tablet (extended-release) - 10mg - oxycodone hydrochloride 10mg - opiate agonists